Naltrexone for alcohol-dependent patients
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background Clinical trials have shown that naltrexone 50 mg/day reduces alcohol consumption and relapse rates in alcohol dependents. Aim To investigate the efficacy of 50mg/day dose of naltrexone in the maintenance of alcohol-dependent subjects over a 36-week treatment period. Methods Subjects were randomised into two equal groups, consisting of 116 male alcohol-dependent patients who met the DSM-IV criteria for alcohol dependence and were seeking treatment. The participants received naltrexone or placebo at a dose of 50 mg/day and were treated in an outpatient clinic, offering a weekly 0.5-hour individual counselling session. Days retained in treatment were measured. Results Forty-one participants (35.3%) completed the 36-week study. Completion rates by group were 44.8% for the 50 mg naltrexone group and 25.9% for the placebo group (chi2=4.56, DF=1, 2-sided significance=0.033). Conclusion The results support the efficacy and safety of naltrexone for outpatient treatment of alcohol-dependent individuals in Iran.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Informed consent: all participants provided informed consent”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Ahmadi 2004
In the citing paper
“bilirubin level and alanine aminotransferase greater than five times normal levels.”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Ahmadi 2004
In the citing paper
“Country: Iran”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Ahmadi 2004
In the citing paper
“Excluded were individuals with other substance use disorders;”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Ahmadi 2004
In the citing paper
“Sample size: 116 (58 intervention, 58 control)”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Ahmadi 2004
19 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Psychiatric disorders in America: the epidemiologic catchment area study
(1991) · Choice Reviews Online · doi:10.5860/choice.28-5931 · Cited by 2,555
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Naltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487
Anton, R. F., Moak, D. H., Waid, L. R., Latham, P. K., Malcolm, R. J., & Dias, J. K. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1758 · Cited by 425
Alteration of ethanol self-administration by naltrexone
Altshuler, H. L., Phillips, P. E., & Feinhandler, D. A. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90257-x · Cited by 397
Chick, J. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.6.587 · Cited by 310
Effect of naltrexone on alcohol “high” in alcoholics
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.613 · Cited by 308
Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference
Froehlich, J. C., Harts, J., Lumeng, L., & Li, T.-K. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90174-g · Cited by 296
Research works printed but not linked: 6
- World Health Organisation. The ICD-10 Classification of Mental and Behavioral Disorders-diagnostic criteria for research (Geneva, World Health Organisation) 1996.
- Anthony JC, Wa rner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substance and inhalants: basic findings from the National Comacology survey.Clin Expl Pharmacol 1994; 2: 244–68.
- Volpicelli JR, Watson NT, King AC, Sherman CE, O’Brien CP. Effect of naltrexone on alcohol “high” in alcoholics.Am J Psychiat 1997; 152: 613- 5.
- Litten RZ, Ferti GJ. International update: new findings on promising medications. Alcoholism:Clin Exp Res 1996; 20: 216A-18A. · DOI
- Volpicelli JR, Davis MA, Olgin JE. Naltrexone blocks the post-shock increase in ethanol consumption.Life Sci 1986; 38: 41–7. · DOI · Paper page
- Hubbell CL, Marglin SH, Sitalnic SJ, Abelson ML, Wild KD, Reid LD. Opioidergic, serotonergic, and dopaminergic manipulations and rats’ intake of a sweetened alcoholic beverage.Alcohol 1991; 8: 355–67. · DOI
Cited by
Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04054.x · Cited by 470
Palpacuer, C., Duprez, R., Huneau, A., Locher, C., Boussageon, R., Laviolle, B., & Naudet, F. (2018) · Addiction · doi:10.1111/add.13974 · Cited by 172
“There were no major differences across studies in terms of subject age (except for one naltrexone study where the adults included were younger than in the others [49]) and sex ratio (except for three naltrexone studies conducted in men only [38,47,48]).”
BackgroundPackages of care for alcohol use disorders in low- and middle-income countries
Benegal, V., Chand, P. K., & Obot, I. S. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000170 · Cited by 94
“Acamprosate (glutamate inhibitor) Three meta-analyses [62,63,66]; two large RCTs including the US COMBINE trial [59,64] Multicenter RCT in combination with out-patient psychosocial intervention in Korean alcoholdependent patients [65]”
BackgroundMethodPalpacuer, C., Hammas, K., Duprez, R., Laviolle, B., Ioannidis, J. P. A., & Naudet, F. (2019) · BMC Medicine · doi:10.1186/s12916-019-1409-3 · Cited by 66
Closing the treatment gap for alcohol use disorders in low- and middle-income countries
Nadkarni, A., Gandhi, Y., Bhatia, U., & Velleman, R. (2023) · Cambridge Prisms: Global Mental Health · doi:10.1017/gmh.2022.57 · Cited by 46
“Naltrexone had a limited impact on drinking outcomes (Ahmadi et al., 2004; Shin et al., 2013), topiramate had mixed results (Baltieri et al.”
Result
Metadata
- Authors
- Ahmadi, J., Babaeebeigi, M., Maany, I., Porter, J., Mohagheghzadeh, M., Ahmadi, N., & Dehbozorgi, G.
- Affiliations
- Shiraz University of Medical Sciences (IR)
- Corresponding author
- Ahmadi, J
- Venue
- Irish Journal of Medical Science
- Published
- 2004-01
- Volume
- 173
- Issue
- 1
- Pages
- 34-37
- ISSN
- 0021-1265 (ISSN-L)
- 1863-4362
- OpenAlex
- W2083502263
- Cited by
- 22
- References
- 25
- Citations by year
- 2023: 1 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 4 · 2013: 1 · 2012: 1
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Irish Journal of Medical Science (1971 -) (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Keywords
- naltrexone, alcoholism, outpatient care, treatment retention, relapse prevention, pharmacotherapy, individual counseling
- MeSH terms
- Adult, Alcoholism, Double-Blind Method, Humans, Iran, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Recurrence, Chi-Square Distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naltrexone for alcohol-dependent patients. https://app.cochat.ai/papers/10.1007/bf02914522
- The paper
- Ahmadi, J., Babaeebeigi, M., Maany, I., Porter, J., Mohagheghzadeh, M., Ahmadi, N., & Dehbozorgi, G. (2004). Naltrexone for alcohol-dependent patients. Irish Journal of Medical Science. https://doi.org/10.1007/bf02914522
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.